Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Urgent U.S. recall issued for Global Pharma Healthcare eye drops

By Brian Buntz | February 3, 2023

artificial tears

[Image courtesy of ezricare-info.com]

Global Pharma Healthcare is voluntarily recalling lubricant eye drops owing to potential contamination. The recall is a result of an investigation by the Centers for Disease Control and Prevention (CDC) into a cluster of multi-state infections linked to the use of the product.

CDC suspects that a cluster of Verona Integron-mediated Metallo-β-lactamase (VIM)- and Guiana-Extended Spectrum-β-Lactamase (GES)- producing carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA) infections are linked to the company’s eye drops.

An FDA notice states that the eye drops may cause serious adverse events, including eye infections, loss of vision and even death.

55 reports of adverse advents

There have been 55 reports of adverse events associated with the eye drops, including eye infections, permanent vision loss and a death associated with a bloodstream infection from May to December 2022.

A number of law firms, including Simmons Hanly Conroy, plan to sue Chennai, India–headquartered Global Pharma Healthcare over the issue.

EzriCare LLC and Delsam Pharma distribute the eye drops in question.

EzriCare has released a statement noting that it first learned of the CDC’s ongoing investigation into a multi-state cluster of Pseudomonas aeruginosa infections on January 20, 2023. The company stated on February 2 that it was “not aware of any testing that definitively links the Pseudomonas aeruginosa outbreak to EzriCare Artificial Tears.”

The company also stressed that it is prepared to cooperate with both CDC and FDA.

EzriCare also highlighted that it was not involved in manufacturing the product, noting that it had “no role in the formulation, packaging delivery system design or actual manufacturing of this product.”

Antibiotic resistance

The bacterial strains associated with the eye drops are resistant to various antibiotics. CDC notes that the isolates it tested were resistant to the antibiotics carbapenem, ceftazidime and cefepime. In addition, the agency found that the subset of isolates tested for susceptibility to ceftazidime-avibactam and ceftolozane-tazobactam were also resistant.

Antibiotic resistance is a growing public health crisis related to the overuse of antibiotics in human medicine, veterinary medicine and agriculture. The issue is making many common infections more difficult to treat, and some infections are now considered untreatable with currently available antibiotics. The problem can lead to extended hospital stays, higher healthcare costs and an increased risk of death.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE